It’s free, but you have to watch the occasional block of ads. It’s worth it, though, for these John Wick movies, which are some of the best action movies ever made. Any action movie fan will ...

VANCOUVER, BC, Jan. 30, 2025 /CNW/ - Power Metals Corp ("Power Metals" or the "Company") (TSXV: PWM) (FRANKFURT: OAA1) (OTCQB: PWRMF) is pleased to announce the appointment of Canaccord Genuity ...

John Travolta, just like Olivia Newton-John, skyrocketed to fame following the release of the film musical Grease in 1978, the year after he danced his way across the big screen in Saturday Night ...

In a report released yesterday, Alex Brooks from Canaccord Genuity reiterated a Buy rating on eEnergy Group (EAAS – Research Report), with a price target of p12.00. The company’s shares opened ...

As of January 29, 2025, the average one-year price target for Dave is $112.35/share. The forecasts range from a low of $90.90 to a high of $141.75. The average price target represents an increase ...

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $130 from $78 and keeps a Buy rating on the shares. The firm is pounding the table on Corcept Therapeutics because of ...

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on home improvement retailer Wickes from 180.0p to 198.0p on Wednesday as a "resilient" Q4 performance drove an upgrade ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as $3 if a key trial succeeds. But the broker said that with a successful Phase III trial, that ...

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each ...

John Werner has created a career out of bringing ideas, networks and people together to generate powerful results. John is a Managing Director and Partner at Link Ventures. John’s deep curiosity ...

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains ...